Novartis psoriasis drug, Cosentyx, receives FDA approval

January 21, 2015 5:56 PM

5 0

The U.S. Food and Drug Administration today approved Cosentyx (secukinumab) to treat adults with moderate-to-severe plaque psoriasis.

Psoriasis is a skin condition that causes patches of skin redness and irritation. Psoriasis is an autoimmune disorder, and occurs more commonly in patients in with a family history of the disease, and most often begins in people between the ages of 15 and 35. The most common form of psoriasis is pla...

Read more

To category page

Loading...